These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30143944)

  • 41. Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients.
    Wattjes MP; Wijburg MT; Vennegoor A; Witte BI; Roosendaal SD; Sanchez E; Liu Y; Martins Jarnalo CO; Richert ND; Uitdehaag BM; Barkhof F; Killestein J
    Mult Scler; 2016 Aug; 22(9):1174-83. PubMed ID: 26564995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.
    Wickström A; Dahle C; Vrethem M; Svenningsson A
    Mult Scler; 2014 Jul; 20(8):1095-101. PubMed ID: 24378984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings.
    Kolcava J; Hulova M; Benesova Y; Bednarik J; Stourac P
    Mult Scler Relat Disord; 2019 May; 30():187-191. PubMed ID: 30785075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
    Prosperini L; Fanelli F; Pozzilli C
    J Neurol Sci; 2016 May; 364():145-7. PubMed ID: 27084235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy of natalizumab in patients with multiple sclerosis according to level of disability: results of an observational study.
    Fernández O; Alvarenga MP; Guerrero M; León A; Alonso A; López-Madrona JC; Leyva L; Oliver B; de Ramón E; Luque G; Fernández V
    Mult Scler; 2011 Feb; 17(2):192-7. PubMed ID: 21088044
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
    Yamout BI; Abou Zeid N; Taha AJ; Zeineddine MM; Khoury SJ
    Mult Scler Relat Disord; 2016 Sep; 9():122-4. PubMed ID: 27645358
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
    Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
    Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
    Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
    Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S;
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):660-668. PubMed ID: 32234967
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Mult Scler; 2012 Dec; 18(12):1760-7. PubMed ID: 22570359
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing.
    van Kempen ZL; Leurs CE; Witte BI; de Vries A; Wattjes MP; Rispens T; Killestein J
    Mult Scler; 2018 May; 24(6):805-810. PubMed ID: 28485678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
    Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
    Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
    González-Suarez I; Rodríguez de Antonio L; Orviz A; Moreno-García S; Valle-Arcos MD; Matias-Guiu JA; Valencia C; Jorquera Moya M; Oreja-Guevara C
    Brain Behav; 2017 Apr; 7(4):e00671. PubMed ID: 28413713
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile.
    Ysrraelit MC; Caride A; Sinay V; Rivera Kindel M; Halfon MJ; Patrucco L; Piedrabuena R; Diaz Aragunde VE
    Arq Neuropsiquiatr; 2021 May; 79(5):407-414. PubMed ID: 34161529
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Practice effect in Symbol Digit Modalities Test in multiple sclerosis patients treated with natalizumab.
    Roar M; Illes Z; Sejbaek T
    Mult Scler Relat Disord; 2016 Nov; 10():116-122. PubMed ID: 27919477
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased relapse activity for multiple sclerosis natalizumab users who become nonpersistent: a retrospective study.
    McQueen RB; Livingston T; Vollmer T; Corboy J; Buckley B; Allen RR; Nair K; Campbell JD
    J Manag Care Spec Pharm; 2015 Mar; 21(3):210-8b. PubMed ID: 25726030
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
    Parfenov V; Du Pasquier R; Schluep M
    Neurologist; 2015 Jun; 19(6):155-7. PubMed ID: 26075469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.